Antibody;1MG;IgG1/kappa;Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab F(ab')2.; ;Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibodies (Cat. No. RIB-Y37) at 2 g/mL, add increasing concentrations of rituximab (10% human serum) and then add Biotinylated Anti-Rituximab Antibodies (Cat. No. RIB-BY35) at 1 g/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/mL.;Demonstration of the specificity of Anti-Rituximab Antibodies (Cat. No. RIB-Y37) to the rituximab.;FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibodies (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 g/ml (Routinely t
